Wafik S El-Deiry
Overview
Explore the profile of Wafik S El-Deiry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
373
Citations
19844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryspayeva D, Seyhan A, MacDonald W, Purcell C, Roady T, Ghandali M, et al.
Oncotarget
. 2025 Mar;
16:168-201.
PMID: 40080721
This article provides a comprehensive analysis of the signaling pathways implicated in breast cancer (BC), the most prevalent malignancy among women and a leading cause of cancer-related mortality globally. Special...
2.
El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, et al.
Oncotarget
. 2025 Mar;
16:140-162.
PMID: 40073368
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed...
3.
Ding E, Pinho-Schwermann M, Zhang S, Purcell C, El-Deiry W
Am J Transl Res
. 2025 Feb;
17(1):104-115.
PMID: 39959215
Objectives: To investigate whether neuroendocrine differentiation (NED) markers, activation of the integrated stress response (ISR), and TRAIL pathway alter neuroendocrine tumor (NET) cell death and ONC201 sensitivity. Methods: We conducted...
4.
Louie A, Huntington K, Lee Y, Mompoint J, Wu L, Lee S, et al.
Am J Cancer Res
. 2025 Feb;
15(1):286-298.
PMID: 39949937
Pancreatic ductal adenocarcinoma (PDAC) has an immunosuppressed, apoptosis-resistant phenotype. TLY012 is pegylated recombinant Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL), an orphan drug for chronic pancreatitis and systemic sclerosis. Innate immune...
5.
MacDonald W, Purcell C, Pinho-Schwermann M, Stubbs N, Srinivasan P, El-Deiry W
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941808
Cancer heterogeneity is a major challenge in oncology, complicating diagnosis, prognostication, and treatment. The clinical heterogeneity of cancer, which leads to differential treatment outcomes between patients with histopathologically similar cancers,...
6.
Wu G, Saftig P, Peters C, El-Deiry W
Oncogene
. 2025 Feb;
44(9):630-631.
PMID: 39934376
No abstract available.
7.
Choucair K, Elliott A, Oberley M, Walker P, Salama A, Saeed A, et al.
BMJ Oncol
. 2025 Jan;
4(1):e000551.
PMID: 39885940
Objective: Cancer patients aged ≥80 years present unique characteristics affecting response to immune checkpoint inhibitors (ICIs), with unidentified molecular differences. This study aimed to explore potential biomarkers of response to...
8.
Purcell C, Srinivasan P, Pinho-Schwermann M, MacDonald W, Ding E, El-Deiry W
Am J Transl Res
. 2025 Jan;
16(12):7972-7982.
PMID: 39822524
Objectives: Prostate cancer (PCa) is a leading cause of cancer death in men worldwide. Approximately 30% of castrate-resistant PCa becomes refractory to therapy due to neuroendocrine differentiation (NED) that is...
9.
Liu J, Farrow M, Seymour L, Desai J, Loong H, Ivy P, et al.
J Clin Oncol
. 2025 Jan;
43(6):735-747.
PMID: 39808749
Purpose: Over the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation of sites, trials, sponsors,...
10.
Strandberg J, Louie A, Lee S, Hahn M, Srinivasan P, George A, et al.
J Clin Invest
. 2025 Jan;
135(5).
PMID: 39808500
Radiotherapy can be limited by pneumonitis, which is impacted by innate immunity, including pathways regulated by TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from toxic...